Medtronic will report its first quarterly earnings since spinning off the MiniMed diabetes unit when it posts third-quarter fiscal 2027 results on Monday, November 24, the company confirmed.
Spin-off complete, margins under pressure
The MiniMed separation closed on October 15, removing the diabetes business from Medtronic’s balance sheet entirely. For the quarter ending in October, analysts surveyed by FactSet expect revenue to rise 6% year over year while adjusted earnings per share dip 2%, according to Yahoo Finance. The company guided fiscal 2027 organic revenue growth of 7.25% to 7.75%, which would mark the strongest top-line expansion in a decade.
Cardiovascular and neuroscience segments are driving the acceleration. Yet the spin-off itself, reinvestment in higher-growth platforms, early-stage manufacturing costs for newer cardiovascular devices, and recent acquisitions are compressing margins in the near term, the Fool.com analysis noted.
The Bottom Line:
- First post-spin earnings print Monday; consensus sees 6% revenue growth offset by a 2% adjusted EPS decline.
- Stock trades at 17x forward earnings with a 2.9% forward yield, but margin compression clouds the “safe dividend” thesis.
- Fiscal 2027 guidance calls for 7.25%-7.75% organic revenue growth — the best clip in ten years.
From turnaround to transition
Medtronic’s earnings declined in fiscal 2023 and 2024, a period the company attributed to supply-chain snarls, inflation, foreign-exchange headwinds, regulatory hurdles in diabetes, and an uneven recovery in elective procedures. The GLP-1 drug wave added competitive pressure on the diabetes franchise. Stability returned in fiscal 2025 and 2026 as costs were stabilized and the cardiovascular and neuroscience portfolios expanded, Yahoo Finance reported.

Fiscal 2026 organic revenue grew 5.8%, the fastest pace in ten years. The MiniMed spin-off, completed mid-October, was designed to sharpen focus on those higher-growth therapeutic areas.
What the street is watching
The alpha metric this quarter is not the top line — it is the adjusted operating margin. Management has signaled that early manufacturing runs for next-generation cardiovascular devices and integration costs from tuck-in acquisitions will weigh on profitability through the first half of fiscal 2027. If margin guidance for the back half of the year holds, the 17x forward multiple could re-rate; if it slips, the dividend yield becomes the primary support.
Institutional holders have been trimming exposure since the spin announcement. 13F filings through September show a net reduction in shares among the top 50 holders, suggesting the “wait-and-see” posture extends beyond retail accounts.

Main Street bridge: your 401(k) and the med-tech supply chain
Medtronic is a staple in broad-market index funds and dividend-focused ETFs. A margin miss on Monday could trigger passive rebalancing flows that hit every S&P 500 tracker.
For patients, the spin-off means MiniMed — now trading independently as MMED — must fund its own R&D pipeline without Medtronic’s balance sheet, potentially altering the pace of insulin-pump innovation. Hospital procurement teams, meanwhile, are watching cardiovascular pricing; early-stage manufacturing costs often get passed through to supply contracts.
Smart money tracker
The Motley Fool’s Stock Advisor team omitted Medtronic from its latest “10 best stocks” list, highlighting names with stronger near-term catalysts. Conversely, the firm’s own disclosure shows it holds a long position in MDT, reflecting a divergence between newsletter positioning and portfolio management. Short interest remains low, per Nasdaq data, indicating skeptics are expressing doubt through underweighting rather than outright bets against.
Next catalyst: the fiscal 2027 third-quarter conference call Monday at 8:00 a.m. ET, where management will update full-year margin guidance and quantify the MiniMed deconsolidation impact.
Disclaimer: The information provided in this article is for educational and market analysis purposes only and does not constitute financial, investment, or legal advice. Always consult with a certified financial professional before making investment decisions.